GlassScriptPhysician profile
Jean Thomas
NPI 1457359945
$4,176.06
in general payments reported to CMS, 2019-2025
23 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 89% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $79.46 · 2021: $112 · 2022: $407 · 2023: $879 · 2024: $1,156 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,221.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $565.83 | 2022-2025 | Rinvoq |
| Sun Pharmaceutical Industries INC. | $471.92 | 2023-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Scientific Affairs, LLC | $470.63 | 2019-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $433.93 | 2023-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $329.21 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $299.36 | 2019-2025 | |
| Pfizer INC. | $279.86 | 2022-2025 | |
| Leo Pharma INC. | $184.24 | 2022-2024 | Adbry |
| Janssen Biotech, INC. | $161.69 | 2023-2025 | Tremfya, Stelara, Simponi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.56 | 2024 | Spevigo |
| Galderma Laboratories, L.P. | $120.87 | 2025 | Nemluvio |
| Genzyme Corporation | $112.28 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.24 | 2020-2025 | Siliq |
| Ucb, INC. | $86.39 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $85.11 | 2023-2025 | Ebglyss, Taltz, Olumiant |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $70.32 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $65.59 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $57.59 | 2023-2024 | Opzelura |
| Genentech USA, INC. | $51.29 | 2025 | Ocrevus Zunovo, Xolair |
| Organon LLC | $47.79 | 2023-2024 | Hadlima |
| Organogenesis INC. | $23.03 | 2023 | Puraply |
| Verrica Pharmaceuticals INC. | $19.70 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $17.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.